CURE10h
FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer
The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.
pharmaphorum6d
Biosimilars in the UK: where are we now and where does the NHS want to go?
Looking further ahead, NHS England envisages savings as a whole from biosimilars of some £400 - £500 million per ... drugs MabThera (rituximab) and Herceptin (trastuzumab).
pharmaphorum1d
FDA approves Herceptin biosimilar as US patent expires
The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...
FiercePharma5d
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
Herceptin sales fell 11% to 1.38 billion Swiss francs ($1.5 billion) over the same period, while Perjeta’s 2024 sales dropped to 3.6 billion Swiss francs ($4 billion) versus roughly 3.8 billion ...
MarketWatch1d
S&P MidCap 400
Cytokinetics Inc. $43.28-1.63-3.63% ...
C&EN6d
Role of Black Tea in the Advancement of Nanotechnology: A Critical Review
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Black tea (BTE), a well-used beverage, has immense applications in nanotechnology. The ...